14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
DMAC vs FENC: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Fennec Pharmaceuticals Inc. (FENC) is the stronger overall head-to-head candidate over DiaMedica Therapeutics Inc. (DMAC) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). DMAC carries a Unified Composite Score of 46.3/100 (HOLD) at $8.41 (N/M Forward P/E, 0.0% operating margin), whereas FENC carries 44.2/100 (HOLD) at $12.00 (11.2x Forward P/E, 5.6% operating margin).
Composite vs. Pillar Nuance: While DMAC currently prints a higher short-term Unified Composite Score (46.3/100 HOLD vs. FENC 44.2/100 HOLD), FENC captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (5.6% vs. 0.0% operating margin) and revenue trajectory (+57.3% vs. +0.0% YoY).
Competes within the Biotechnology value chain with $405.7M market capitalization and 5.6% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ DMAC vs FENC Key Questions & Quantitative Answers
As of Nov 16, 2026, Fennec Pharmaceuticals Inc. (FENC) is the stronger overall head-to-head candidate over DiaMedica Therapeutics Inc. (DMAC) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). DMAC carries a Unified Composite Score of 46.3/100 (HOLD) at $8.41 (N/M Forward P/E, 0.0% operating margin), whereas FENC carries 44.2/100 (HOLD) at $12.00 (11.2x Forward P/E, 5.6% operating margin). Composite vs. Pillar Nuance: While DMAC currently prints a higher short-term Unified Composite Score (46.3/100 HOLD vs. FENC 44.2/100 HOLD), FENC captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (5.6% vs. 0.0% operating margin) and revenue trajectory (+57.3% vs. +0.0% YoY).
FENC leads the Growth & Scale pillar: DMAC posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with FENC at +57.3% YoY revenue growth and +0.0% YoY earnings growth on $66M TTM revenue (94.1% gross margin, 5.6% operating margin). Across the 6-period historical trajectory (FY2018 to FY2025), DMAC cumulative revenue shifted N/A while FENC shifted +100.0%. In operating R&D and SG&A reinvestment, DMAC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for FENC.
FENC screens cheaper on headline valuation multiples. DMAC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas FENC trades at 11.2x Forward P/E, 12.6x Trailing P/E, 1.47x PEG, and 6.1x EV/Revenue (-3.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DMAC (-114.6% ROE) versus FENC (9.1% ROE) capital efficiency.
In options market volatility and institutional positioning, DMAC carries 106.3% implied volatility (14th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (1.74β · 98% Vol realized risk). By comparison, FENC carries 216.9% implied volatility (24th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.71β · 69% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.